drugset / Trial / NCT00142571
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Phase 3
Completed
120 enrolled
Memorial Sloan Kettering Cancer Center
Connective Tissue Oncology Society · collabM.D. Anderson Cancer Center · collabMassachusetts General Hospital · collabMayo Clinic · collabUniversity of Michigan Rogel Cancer Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.
Timeline
- Start
- 2003-01
- Primary completion
- —
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |